• 来稿:陈琳   北京市虹天济神经科学研究院

  • Clin Neurol Neurosurg. 2006  Mar;108(3):250-4.

  •  

  • Neuroprotection in multiple  sclerosis

  •  

  • Karussis D, Grigoriadis S, Polyzoidou E,  Grigoriadis N, Slavin S, Abramsky O.

  • Department of Neurology and the  Agnes Ginges Center  for Neurogenetics, Laboratory of Neuroimmunology, Hadassah University Hospital, Jerusalem,  Ein-Karem IL-91120, Israel. karus@cc.huji.ac.il

  •  

  • In chronic inflammatory diseases like  multiple sclerosis (MS), neuroprotection refers to strategies aimed at  prevention of the irreversible damage of various neuronal and glial cell  populations, and promoting regeneration. It is increasingly recognized that MS  progression, in addition to demyelination, leads to substantial irreversible  damage to, and loss of neurons, resulting in brain atrophy and cumulative  disability. One of the most promising neuroprotective strategies involves the  use of bone marrow derived stem cells. Both hematopoietic and non-hematopoietic  (stromal) cells can, under certain circumstances, differentiate into cells of  various neuronal and glial lineages. Neuronal stem cells have also been reported  to suppress EAE by exerting direct in situ immunomodulating effects, in addition  to their ability to provide a potential source for remyelination and  neuroregeneration. Preliminary results from our laboratory indicate that  intravenous or intracerebral/intraventricular injection of bone marrow derived  stromal cells could differentiate in neuronal/glial cells and suppress the  clinical signs of chronic EAE. Both bone marrow and neuronal stem cells may  therefore have a therapeutic potential in MS. It seems that future treatment  strategies for MS should combine immunomodulation with neuroprotective  modalities to achieve maximal clinical benefit.


干细胞治疗颞叶性癫痫展望
FK506和环孢霉素A对新生期轴突切断后运动神经元的保护作用

Previous:

Next:

多发性硬化中的神经保护